panitumumab,bevacizumab
roche,amgen,takeda
['colorectal', 'beva', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bevacizumab', 'crcsm', 'panitumumab', 'rectal']
superior efficacy was observed when patients with ras wild type metastatic colorectal cancer were treated with panitumumab plus chemotherapy vs bevacizumab in the first-line setting. #crcsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.